Revenue beat consensus but EPS missed, with GAAP net income declining sharply YoY due to acquisition-related costs and higher R&D spending. The reiterated guidance provides no catalyst; watch for upcoming orexin pipeline data readouts (ADHD, idiopathic hypersomnia) and LUMRYZ prescription trends as key drivers.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 3 $45.69entry
- T+1 · 13h ago +0.44%α −1.21% · $45.89
- T+5 · in 5d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Alkermes reported Q3 2026 total revenue of $480.1M, up 21.8% YoY from $394.2M, driven by LUMRYZ ($89.9M) and growth in VIVITROL and ARISTADA. The company reiterated its full-year 2026 financial expectations, including total revenue of $1.73B-$1.84B and GAAP net loss of ($95M)-($115M).
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $480.1M, up 21.8% YoY from $394.2M
- Revenue of $480.1M vs consensus of $463.5M (beat)
- GAAP net income of $16.3M vs $82.8M in Q3 2025
- Adjusted EBITDA of $120.1M vs $121.5M in Q3 2025
- LUMRYZ net sales of $89.9M; approximately 4,100 patients on therapy
- VIVITROL net sales of $127.6M, ARISTADA $103.9M, LYBALVI $95.9M
- Company reiterated 2026 financial expectations (revenue $1.73B-$1.84B, GAAP net loss ($95M)-($115M))
- Cash and investments of $787.6M at Sept. 30, 2026, up from $691.6M at June 30, 2026
Financial Impact
Revenue beat consensus by $16.6M (3.6%); GAAP EPS missed consensus by $0.16 (64% miss); full-year guidance unchanged
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VIVITROL | $127.6M | +5.4% |
| ARISTADA | $103.9M | +5.9% |
| LYBALVI | $95.9M | -2.3% |
| LUMRYZ | $89.9M | Not reported |
Risk Factors
- GAAP EPS miss of $0.16 vs consensus may pressure the stock near-term
- GAAP net income declined 80% YoY due to Avadel acquisition costs and higher operating expenses
- LUMRYZ net sales of $89.9M were down from $96.6M in Q2 2026, suggesting potential quarter-over-quarter deceleration
- R&D spending rose 48% YoY to $121.1M, pressuring margins
- Long-term debt of $1.5B from Avadel acquisition increases financial leverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-444381 |
| Document: alks-20261103.htm | 0001193125-26-444381 |
| Document: alks-ex99_2.htm | 0001193125-26-444381 |
| Document: 0001193125-26-444381-index-headers.html | 0001193125-26-444381 |
| Document: 0001193125-26-444381-index.html | 0001193125-26-444381 |
| Document: 0001193125-26-444381.txt | 0001193125-26-444381 |
| 8-K Data (Synthetic) | 0001193125-26-444381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | Institutional Cluster | $46.17 | awaiting T+60 | awaiting T+60 | $45.69 (−1.04%) |
Nov 3, 2026 1d ago | 144 | $46.17 | awaiting T+60 | awaiting T+60 | $45.69 (−1.04%) |
Nov 3, 2026 1d ago | 8-K | $45.69 | awaiting T+60 | awaiting T+60 | $45.69 (−0.00%) |
Sep 21, 2026 6w ago | 8-K | $44.00 | awaiting T+60 | awaiting T+60 | $45.69 (+3.85%) |
Sep 16, 2026 7w ago | 8-K | $46.07 | awaiting T+60 | awaiting T+60 | $45.69 (−0.82%) |
Sep 3, 2026 8w ago | Insider Cluster | $46.10 | awaiting T+60 | awaiting T+60 | $45.69 (−0.89%) |
Aug 3, 2026 13w ago | Insider Cluster | $49.67 $44.32 | ▲ +10.77% | ▲ +11.15% | $45.69 (+8.01%) |
Aug 3, 2026 13w ago | Insider Cluster | $49.67 $44.32 | ▼ −10.77% | ▼ −11.15% | $45.69 (−8.01%) |
Aug 3, 2026 13w ago | Insider Cluster | $49.67 $44.32 | ▼ −10.77% | ▼ −11.15% | $45.69 (−8.01%) |
Jul 28, 2026 14w ago | 8-K | $50.50 $43.48 | ▲ +13.90% | ▲ +18.25% | $45.69 (+9.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers